
Intellia pauses gene therapy trial due to liver injury
Intellia Therapeutics announced it has temporarily paused its MAGNITUDE and MAGNITUDE-2 Phase III clinical trials of nex-z for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN), respectively. The action follows a report of Grade 4 liver transaminases and increased total bilirubin in a patient who… Read More














